Three of the companies making drugs used in the Phase II I-SPY COVID-19 study - Amgen, AbbVie and Takeda - announced the patient enrollments Monday. The study, which will enroll up to 1,500 critically ill patients, could test around 10 drugs.
Bristol-Myers Squibb said Celgene would sell the drug, Otezla (apremilast), to Amgen. The pharmaceutical company had said it would seek a divestment of the drug to satisfy competition concerns from the FTC.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The drugmaker said Monday it would sell off the drug Otezla to address concerns about competition that the Federal Trade Commission had expressed in connection to the pending $74 billion deal. According to an analyst, BMS saw Otezla as competitive against its investigational TYK2 inhibitor.